Used in pharmaceutical research as a potent and selective inhibitor of Janus kinase 2 (JAK2), particularly in the development of treatments for myeloproliferative disorders. It shows promise in targeting abnormal signaling pathways involved in blood cancer cell proliferation. Its structure allows for high binding affinity to the JAK2 enzyme, improving specificity and reducing off-target effects. Also investigated for anti-inflammatory applications due to JAK-STAT pathway involvement in immune regulation.